title: Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13.
abstract: We examined whether the expression and activation of pro-matrix metalloproteinase (MMP)-1 varies from that of pro-MMP-13 in the joint fluid of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. To do this, joint fluid was collected from 34 RA and 34 OA patients. The collagenase (pro-MMP-1 and MMP-13, total MMP-1, and MMP-13), gelatinase (total MMP-2 and MMP-9), stromelysin (total MMP-3), matrilysin (total MMP-7), uPA, and tissue inhibitor of MMP (TIMP) levels were measured by ELISA. The level of total MMP-1 in RA joint fluids was similar to that of the OA joint fluid. In contrast, the level of total MMP-13 in the RA group was significantly higher than that of the OA group. Among various MMPs (MMP-2, MMP-3, MMP-7, and MMP-9), only MMP-9 was strongly associated with total MMP-13 in both RA and OA. The level of uPA was also strongly associated with MMP-13 in RA but not OA, while the level of TIMP-1 and TIMP-2 was not significantly different between RA and OA. In conclusion, MMP-9 and uPA might be involved in the activation of pro-MMP-13 through unknown mechanisms in arthritic diseases.
authors.affiliation: East-West Bone and Joint Research Institute, Kyung Hee University Hospital at KANGDONG, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea. labrea46@yahoo.co.kr
authors.forename: Kyoung Soo
authors.initials: KS
authors.lastname: Kim
authors.forename: Yeon-Ah
authors.initials: YA
authors.lastname: Lee
authors.forename: Hyun Mi
authors.initials: HM
authors.lastname: Choi
authors.forename: Myung Chul
authors.initials: MC
authors.lastname: Yoo
authors.forename: Hyung-In
authors.initials: HI
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000201:enzymology*; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000032:analysis; D053509:Matrix Metalloproteinase 13 / Q000032:analysis*; D020778:Matrix Metalloproteinase 2 / Q000032:analysis; D019278:Matrix Metalloproteinase 3 / Q000032:analysis; D020783:Matrix Metalloproteinase 7 / Q000032:analysis; D020780:Matrix Metalloproteinase 9 / Q000032:analysis*; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy / Q000201:enzymology*; D013582:Synovial Fluid / Q000201:enzymology*; D019714:Tissue Inhibitor of Metalloproteinases / Q000032:analysis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
chemical_list: D018501:Antirheumatic Agents; D004792:Enzyme Precursors; D019714:Tissue Inhibitor of Metalloproteinases; D014568:Urokinase-Type Plasminogen Activator; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3; C060932:MMP7 protein, human; D020783:Matrix Metalloproteinase 7; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; C522360:MMP1 protein, human; D020781:Matrix Metalloproteinase 1